Table 5.
Potential utility of antimicrobial agents for laboratory-confirmed etiologic diagnoses among HIV-infected participants meeting Integrated Management of Adolescent and Adult Illness criteria for septic shock, severe respiratory distress without shock, severe pneumonia, and among those who died in-hospital of febrile illness, Moshi, Tanzania 2007–2008
| Septic shock (N = 14) | Severe respiratory distress without shock (N = 26) | Severe pneumonia (N = 54) | In-hospital death (N = 31) | |
|---|---|---|---|---|
| Ceftriaxone utility (%) | 9 (64) | 3 (12) | 9 (17) | 6 (19) |
| Ampicillin + gentamicin utility (%)* | 7 (50) | 4 (15) | 7 (13) | 2 (6) |
| Tetracylines utility (%) | 0 | 2 (8) | 5 (9) | −† |
| Amphotericin utility (%) | 2 (14) | 5 (19) | 8 (15) | 5 (16) |
| Anti-tuberculosis therapy utility (%) | 1 (7) | 2 (8) | 3 (6) | 2 (7) |
NOTE: Denominator for percentage (%) derived from total number of patients within each group, not from total number of diagnoses.
Ampicillin/gentamicin utility calculation includes participants with invasive pneumococcal disease diagnosed by urine antigen and susceptibility of these cases to ampicillin is extrapolated from the study antibiogram (57% of pneumococcal blood isolates were susceptible to ampicillin).
Convalescent serology required to diagnose Q fever, spotted fever group rickettsioses, therefore no confirmed cases among the In-hospital death group.